Renal Denervation

July 31, 2014 — Radiation therapy may offer a promising new noninvasive alternative treatment for the millions of Americans whose high blood pressure doesn’t respond to medication, suggests preliminary research presented at the 56th annual me...

Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

SYMPLICITY HTN-3 TRial, ACC.14, renal denervation

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial. This trial data was presented to a packed, standing-r...

renal denervation

One of the exciting new frontiers for interventional cardiology is the use of renal denervation therapy to treat pharmacologically uncontrolled hypertension. It is estimated there are more than 10 million drug-resistant hypertension patients...

Twelve-month Data St. Jude Medical EnligHTN Renal Denervation System
St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment...
September 2, 2014 — Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial,...
September 2, 2014 — Renal denervation reduces recurrent atrial fibrillation (AF) when performed with pulmonary vein isolation ablation in patients with AF and...
July 31, 2014 — Radiation therapy may offer a promising new noninvasive alternative treatment for the millions of Americans whose high blood pressure doesn’t...

Articles

July 31, 2014 — Radiation therapy may offer a promising new noninvasive alternative treatment for the millions of Americans whose high blood pressure doesn’t...
Journal of Endovascular Therapy Hypertension Renal Denervation Therapy
Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 
Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy...
Medtronic, symplicity, renal denervation
Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed...

Video Center

By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
3 weeks 6 days ago
As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
7 weeks 23 hours ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
12 weeks 6 days ago
This webinar will discuss why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...

Comparison Charts

Sorry there is no data available